Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable

被引：0
|
作者：
Yuen, Lisa [1 ,2 ]
Gogakos, Tasos [1 ,2 ,3 ]
Boiocchi, Leonardo [4 ]
Hobbs, Gabriela [2 ,5 ]
Hasserjian, Robert [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA
[5] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年
关键词：
D O I：
10.1002/ajh.27530
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Epidemiology of primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV) in the European Union (EU)
    Mehta, J.
    Le-Ruyet, O.
    Fryzek, J.
    Iqbal, S. U.
    Mesa, R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S323 - S324
  • [32] Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Apostolidou, Effrosyni
    Kantarjian, Hagop
    Thomas, Deborah
    Burger, Ian
    Borthakur, Gautam
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 281 - 284
  • [33] Myelofibrotic Transformations of Polycythemia Vera and Essential Thrombocythemia are Morphologically, Biologically, and Prognostically Indistinguishable From Primary Myelofibrosis
    Sangle, Nikhil
    Cook, Josh
    Perkins, Sherrie
    Teman, Carolin J.
    Bahler, David
    Hickman, Kimberly
    Wilson, Andrew
    Prchal, Josef
    Salama, Mohamed E.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2014, 22 (09) : 663 - 668
  • [34] Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
    Barbui, T.
    Thiele, J.
    Vannucchi, A. M.
    Tefferi, A.
    BLOOD CANCER JOURNAL, 2015, 5 : e337 - e337
  • [35] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
    Sliwa, Thamer
    Beham-Schmid, Christine
    Burgstaller, Sonja
    Buxhofer-Ausch, Veronika
    Gastl, Guenther
    Geissler, Klaus
    Krauth, Maria
    Krippl, Peter
    Lang, Alois
    Petzer, Andreas
    Woehrer, Stefan
    Woelfler, Albert
    Gisslinger, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (9-10) : 293 - 302
  • [36] Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (06) : 491 - 497
  • [37] The glucocorticoid receptor A3669G SNP is not associated with polycythemia vera, essential thrombocythemia or primary myelofibrosis
    Costache, Roxana M.
    Banescu, Claudia
    Popp, Radu A.
    Pop, Ioan V.
    Trifa, Adrian P.
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 209 - 211
  • [38] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
    Thamer Sliwa
    Christine Beham-Schmid
    Sonja Burgstaller
    Veronika Buxhofer-Ausch
    Günther Gastl
    Klaus Geissler
    Maria Krauth
    Peter Krippl
    Alois Lang
    Andreas Petzer
    Stefan Wöhrer
    Albert Wölfler
    Heinz Gisslinger
    Wiener klinische Wochenschrift, 2017, 129 : 293 - 302
  • [39] Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis
    Lucijanic, Marko
    Krecak, Ivan
    Soric, Ena
    Sabljic, Anica
    Galusic, Davor
    Holik, Hrvoje
    Perisa, Vlatka
    Peric, Martina Moric
    Zekanovic, Ivan
    Kusec, Rajko
    LEUKEMIA RESEARCH, 2022, 119
  • [40] Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
    A Tefferi
    L Saeed
    C A Hanson
    R P Ketterling
    A Pardanani
    N Gangat
    Leukemia, 2017, 31 : 2851 - 2852
12345